Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast -2023 - EU5

Publisher Name :
Date: 01-Nov-2016
No. of pages: 60
This report is available at upto 40% Discount. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-EU5" Report provides an overview of the disease and market size of the CMV for the EU5 (France, Germany, Italy, Spain and United Kingdom) for 2013-2023. It also includes historical and forecast edepidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013-2023.

According to DelveInsight, the total number of Diagnosed Cytomegalovirus (CMV) infection cases in France is expected to increase at a CAGR of 0.06% to 20,871 cases by 2023. In case of Germany it is expected to increase at a CAGR of 0.067% to 21,619 cases by 2023. In United Kingdom, the total number of Diagnosed Cytomegalovirus (CMV) infection cases is expected to increase at a CAGR of 0.061% to 14,417 cases by 2023 and in Spain is expected to increase at a CAGR of 0.029% to 12,810 cases in 2023. For Italy, it is expected to increase at a CAGR of 0.031% to 13,358 cases in 2023. CMV infection is most prevalent in Italy and least prevalent in Spain of the EU5.

As per DelveInsight's estimation, the market size of Cytomegalovirus (CMV) infection shall reach to USD 50.2 Million in Italy, USD 213.3 Million in Germany, USD 142.3 Million in France, USD 62.8 Million in Spain and USD 63.8 Million in United Kingdom by the end of 2023. Italy has the lowest and Germany has the highest market size of the EU5.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

- Marketed information including available prescription drugs.

- The Report also covers the detailed historical and forecasted epidemiological data covering Spain, Italy, United Kingdom, Germany, and France from 2013-2023.

- It also provides Market size of Cytomegalovirus (CMV) infection for Spain, Italy, United Kingdom, Germany, and France from 2013 and forecasted Market size to 2023.

Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast -2023 - EU5

Table of Contents

Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Treatment Algorithm for Cytomegalovirus Infections
Treatment for Congenital CMV Infection
Treatment of Ganciclovir resistant CMV
Treatment Guidelines
Recommendations for Treating Cytomegalovirus Infections
Disease Management
Epidemiology and Patient Population
Europe
Assumptions and Rationale
Italy
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Spain
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
United Kingdom
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Germany
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
France
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Unmet Medical Needs
Marketed Products
Valcyte (Valganciclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
FOSCAVIR (foscarnet sodium)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoTect CP
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Valtrex (Valacyclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Emerging Products Analysis
Emerging Therapies
1. Approved Products
Cytovir CMV: Cell Medica Ltd.
Product Description
Research and Development
Product Development Activities
2. Pipeline Products (Phase III)
CytoTect CP 70: Biotest AG.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Letermovir: Merck & Co.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Brincidofovir: Chimerix Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
ASP0113: Astellas Pharma Global Development, Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Human Cytomegalovirus Immune Globulin: CSL Behring
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Europe Market Size
Italy
Germany
France
Spain
United Kingdom
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Table 2: CMV Patients among Transplants in Italy (2013-2023)
Table 3: Infants Patients at High Risk of CMV in Italy (2013-2023)
Table 4: HIV Patients at High Risk of CMV in Italy (2013-2023)
Table 5: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Table 6: CMV Patients among Transplants in Spain (2013-2023)
Table 7: Infants Patients at High Risk of CMV in Spain (2013-2023)
Table 8: HIV Patients at High Risk of CMV in Spain (2013-2023)
Table 9: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Table 10: CMV Patients among Transplants in United Kingdom (2013-2023)
Table 11: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 12: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Table 14: CMV Patients among Transplants in Germany (2013-2023)
Table 15: Infants Patients at High Risk of CMV in Germany (2013-2023)
Table 16: HIV Patients at High Risk of CMV in Germany (2013-2023)
Table 17: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Table 18: CMV Patients among Transplants in France (2013-2023)
Table 19: Infants Patients at High Risk of CMV in France (2013-2023)
Table 20: HIV Patients at High Risk of CMV in France (2013-2023)
Table 21:Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 22:Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 23: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 24: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 25: Total Market size of Cytomegalovirus (CMV) Infection USD, Million (2013-2023)

List of Figures

Figure 1: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Figure 2: CMV Patients among Transplants in Italy (2013-2023)
Figure 3: Infants Patients at High Risk of CMV in Italy (2013-2023)
Figure 4: HIV Patients at High Risk of CMV in Italy (2013-2023)
Figure 5: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Figure 6: CMV Patients among Transplants in Spain (2013-2023)
Figure 7: Infants Patients at High Risk of CMV in Spain (2013-2023)
Figure 8: HIV Patients at High Risk of CMV in Spain (2013-2023)
Figure 9: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Figure 10: CMV Patients among Transplants in United Kingdom (2013-2023)
Figure 11: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Figure 12: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Figure 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Figure 14: CMV Patients among Transplants in Germany (2013-2023)
Figure 15: Infants Patients at High Risk of CMV in Germany (2013-2023)
Figure 16: HIV Patients at High Risk of CMV in Germany (2013-2023)
Figure 17: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Figure 18:CMV Patients among Transplants in France (2013-2023)
Figure 19: Infants Patients at High Risk of CMV in France (2013-2023)
Figure 20: HIV Patients at High Risk of CMV in France (2013-2023)
Figure 21: Total Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 22: US Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 23: Italy market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 24: Germany market size of Cytomegalovirus (CMV) Infection in USD, Million (2013-2023)
Figure 25: France market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
  • Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016
    Published: 07-Dec-2016        Price: US 2000 Onwards        Pages: 250
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and sy......
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016
    Published: 07-Dec-2016        Price: US 2000 Onwards        Pages: 45
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline landscape.MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialy......
  • Europe Ganciclovir Market Report 2016
    Published: 05-Dec-2016        Price: US 3900 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Ganciclovir Revenue, means the sales value of Ganciclovir This report studies sales (consumption) of Ganciclovir in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Roche - Bausch & Lomb - Fresenius Kabi - Luitpold - Huatai Pha......
  • Global Meningococcal Infections Vaccine Market Professional Survey Report 2016
    Published: 05-Dec-2016        Price: US 3500 Onwards        Pages: 106
    Notes: Production, means the output of Meningococcal Infections Vaccine Revenue, means the sales value of Meningococcal Infections Vaccine This report studies Meningococcal Infections Vaccine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global ma......
  • Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Sales Market Report 2016
    Published: 05-Dec-2016        Price: US 4000 Onwards        Pages: 105
    Notes: Sales, means the sales volume of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Revenue, means the sales value of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections This report studies sales (consumption) of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for ......
  • Impetigo - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 45
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2016, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabet......
  • Q Fever - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 41
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2016, provides an overview of the Q Fever (Infectious Disease) pipeline landscape.Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscle pain. Risk factors include occupations. Treatment includes antibiotics.......
  • Hepatitis B - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 389
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal p......
  • Hand, Foot and Mouth Disease - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 36
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, he......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs